The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety

• Published in: Psychopharmacologia Vol. 121; no. 2; pp. 186 - 191
• Main Authors: WALSH, D. M, STRATTON, S. C, HARVEY, F. J, BERESFORD, I. J. M, HAGAN, R. M
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01-09-1995
• Subjects: Animals; Anti-Anxiety Agents - pharmacology; Anxiety - drug therapy; Behavior, Animal - drug effects; Biological and medical sciences; Disease Models, Animal; Indoles - pharmacology; Locomotion - drug effects; Male; Medical sciences; Mice; Mice, Inbred Strains; Neuropharmacology; Pharmacology. Drug treatments; Piperidines - pharmacology; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Receptors, Neurokinin-2 - antagonists & inhibitors; Chemotherapy; NK2 receptor; Tranquillizer; Psychotropic; Animal; Treatment efficiency; Anxiety disorder; Subcutaneous administration; Anxiety; Antagonist
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/BF02245629

The non-peptide NK2 receptor antagonist, GR159897, was evaluated in two putative models of anxiety, the mouse light-dark box and the marmoset human intruder response test. Effects were compared to the structurally dissimilar NK2 antagonist, (+/-) SR48968 and the benzodiazepines, diazepam and chlordiazepoxide. GR159897 (0.0005-50 micrograms/kg SC) caused significant and dose-dependent increases in the amount of time mice spent in the more aversive light compartment of the light-dark box, with no effect on locomotor activity. (+/-)SR48968 (0.0005-0.5 microgram/kg SC) and diazepam (1-1.75 mg/kg SC), also increased time spent in the light compartment, without effect on locomotor activity. In the marmoset human intruder response test, GR159897 (0.2-50 micrograms/kg SC) significantly increased the amount of time marmosets spent at the front of the cage during confrontation with a human observer ("threat"). Similar effects were produced by (+/-)SR48968 (10-50 micrograms/kg SC) and chlordiazepoxide (0.3-3.0 mg/kg SC). These results provide further evidence, in both rodent and primate species, for the ability of NK2 antagonists to restore behaviours which have been suppressed by novel aversive environments. Such effects indicate that NK2 antagonists may have anxiolytic activity.